Patients with minor embolism, or even massive embolism but stable circulation, are treated with heparin followed by oral anticoagulants. If recurrent pulmonary embolism occurs during this treatment or if anticoagulation is contraindicated, then venous interruption should be considered.

**General supportive measures in acute massive pulmonary embolism**

Patients in pain should receive analgesia but opiates should be used with caution in the hypotensive patient. When hypoxemia is refractory to oxygen supplementation by face mask, intubation and mechanical ventilation may be necessary, but this may cause the haemodynamic situation to deteriorate further by impeding venous return. When the cardiac output is reduced, the dilated right ventricle is hypoxic and already near maximal stimulation from the high concentration of endogenous catecholamines; it is unlikely to respond to inotropic agents, which may do no more than precipitate arrhythmias. When necessary because of a dangerous fall of systemic pressure, the judicious use of noradrenaline (norepinephrine) titrated against a moderate increase in blood pressure might be beneficial in improving right ventricular function and systemic haemodynamics. The right atrial pressure should be maintained at a high level (15 mm Hg) since this filling pressure is necessary for the failing right ventricle to maintain its output; if the right atrial pressure falls for any reason, administration of fluid is helpful. However, fluid loading might be detrimental in case of frank right ventricular distention and high filling pressure, since it may augment ventricular interaction both by increasing pericardial pressure and by shifting the ventricular septum leftwards, thus decreasing left ventricular preload and output. Vasodilators should be avoided at all times; an exception to this rule may in the future be selective pulmonary vasodilatation by inhalation of nitric oxide or prostacyclin.

In the absence of circulatory failure, routine monitoring is sufficient. In patients with shock, at least a central venous line should be inserted to permit repeated measurements of pressure and the administration of drugs. Monitoring with a pulmonary artery catheter is useful in estimating the response to treatment. When thrombolytic treatment is considered, the antecubital route should be preferred and insertion of arterial lines avoided.

**Heparin**

UFH is the standard treatment after thrombolysis and for all patients who do not have severe circulatory embarrassment. Heparin acts by catalysing the effect of antithrombin III (ATIII), so that this inhibitor efficiently combines with and inactivates a number of serine proteases, notably thrombin (factor IIa), factor
Xa (fXa), and factor IXa. Of these three enzymes, thrombin is the most sensitive to inhibition by heparin-ATIII. In addition, heparin catalyses the inactivation of thrombin by another plasma cofactor, heparin cofactor II, which acts independently of ATIII.12

Heparin actually constitutes “secondary prevention” of recurrent pulmonary embolism rather than primary treatment. It substantially reduces morbidity and mortality from pulmonary embolism by preventing further fibrin deposition on the thrombus. This stops the formation and growth of thrombi and allows the patient’s native fibrinolytic mechanisms to destroy both the emboli that have occurred already and thrombi that are potential further emboli. However, heparin does not directly dissolve thrombus that already exists.

The efficacy of heparin treatment depends on achieving a critical therapeutic concentration of heparin within the first few hours of treatment. Prompt and adequate treatment with UFH, followed by oral anticoagulation for at least three months, results in an 80–90% risk reduction for both recurrent venous thromboembolism and death. UFH also rapidly reduces the mediator induced pulmonary vasoconstriction and bronchoconstriction from thrombin activation and platelet aggregation.

UFH can be given by subcutaneous injection, by continuous infusion or as intermittent boluses four hourly. Haemorrhage is slightly more common with the bolus technique; however, because patients receiving UFH in boluses usually receive greater doses of the drug, it is uncertain whether the difference noted in the rates of bleeding is related to the method of heparin administration or to the difference in the total dose of UFH given. With subcutaneous injection an adequate anticoagulant response is not achieved in the first 24 hours unless a starting dose of at least 17 500 U (or 250 U/kg) every 12 hours is used.1

Before initiation of heparin treatment, a screening test for the activated partial thromboplastin time (aPTT), prothrombin time, and platelet count are usually sufficient. The main purpose of the screen is to obtain a pretreatment aPTT from the individual patient as a basis of therapeutic control. The presence of antiphospholipid antibodies can be suspected by a prolongation of the aPTT. It is also important to establish a baseline platelet count should heparin induced thrombocytopenia complicate subsequent treatment. Pretherapeutic screening is particularly desirable in patients with a high risk of bleeding, and those with liver or renal disorders.

Because UFH binds to several plasma, platelet, and endothelial proteins (some of them are acute phase reactants, the concentrations of which are raised in sick patients), its plasma concentrations and anticoagulant response are unpredictable, even with weight based dosing. Therefore, careful control of the level of anticoagulation and dose adjustments for the prevention of complications and for the improvement of therapeutic efficacy are mandatory.

The most commonly used clotting test is the aPTT, which is a global coagulation test (sensitive to the inhibitory effects of heparin on thrombin, fXa, and fIXa). Different reagents and coagulation timers make the aPTT quite variable relative to a given heparin concentration. The current recommendation is to give sufficient UFH to prolong the aPTT to a range that corresponds to a plasma heparin concentration of 0.2–0.4 U/ml by protamine titration. This relation can be established a priori by a simultaneous comparison of aPTT and plasma heparin concentrations in 20–30 patients receiving heparin. Once the therapeutic range for the aPTT is known, monitoring of plasma heparin concentrations is seldom necessary. If the laboratory changes its coagulation timer or uses a different thromboplastin for the aPTT,
the correlation between aPTT and plasma heparin concentrations should be reestablished.

The aPTT test should be performed 4–6 hours after initiation of the treatment and repeated six hours after any change of dosage, and subsequently at least daily. The aPTT should be maintained at 1.5–2.5 times the patient pretreatment or the laboratory mean control value. Failure to achieve this range is associated with an increased risk of recurrent venous thromboembolism. In contrast, there is only a weak association between supratherapeutic aPTT response and the risk of bleeding. A weight based UFH dosing nomogram is useful in rapidly achieving therapeutic goals while avoiding prolonged periods of excessive anticoagulation (table 1). When the bolus method is used, control is difficult because of the wide swings that occur in the plasma heparin concentrations. The best that can be achieved to prevent gross over- or under-anticoagulation is ensuring that there is only a slight prolongation of clotting just before the next dose. If the aPTT is prolonged before UFH is started the possibility of antiphospholipid antibodies should be considered, and in these circumstances the concentration of heparin itself should be assayed. A heparin dose greater than 40 000 U/day should not be administered unless a heparin concentration < 0.2 U/ml is confirmed. True heparin resistance is mainly caused by ATIII deficiency.

The correct duration of heparin treatment for a major pulmonary embolism should be at least a week. Oral anticoagulants are started together with heparin treatment and these should be administered jointly for at least five days; heparin may be discontinued when the prothrombin time yields an international normalised ratio (INR) above 2.0 on two consecutive days.

Recurrent pulmonary embolism may occur during the first few days of heparin treatment before the clot becomes adherent to the endothelium and does not constitute a therapeutic failure. Many patients who suffer recurrence while receiving heparin will be found to be inadequately anticoagulated as reflected by an aPTT below the therapeutic range. Increasing the dose of heparin should be the initial alteration in treatment in these patients.

Haemorrhagic complications occur in up to 15% of patients on full dose heparin, but are serious in less than 5%. They are most likely if the patient has a potential source of bleeding such as an active peptic ulcer or any of a wide variety of risk factors, the most important of which are a pre-existing bleeding tendency, uraemia, advanced age, recent surgery or trauma, severe hypertension, previous gastrointestinal haemorrhage, and concomitant anti-platelet treatment. Blood transfusion will correct massive blood loss, but prolonged in a slow infusion (10–20 minutes) is the specific antidote. One milligram of protamine neutralises about 100 U of UFH, but no more than 50 mg should be given with a single infusion unless a large overdose of heparin is known to have occurred. Heparin treatment is absolutely contraindicated if the patient has had a recent haemorrhagic stroke.

Occasionally, prolonged administration of high dose heparin (over two months at > 15 000 U daily, used mainly in pregnant patients) leads to osteoporosis. The patient receiving long term heparin should be monitored with tests of bone density, and heparin should be discontinued when bone loss is shown to be progressive. No preventive treatment has been proven effective for heparin induced osteopenia, although supplements of calcium and vitamin D are often given. Skin necrosis and hypersensitivity reactions to heparin are rare. Very rarely, continuous heparin infusion over a few days causes aldosterone depression by an unknown mechanism, which may cause clinically important hyperkalaemia in certain patients—for example, those with renal failure or diabetes.

UFH causes transient mild thrombocytopenia in about 10% of patients and severe thrombocytopenia in less than 5%. The milder variety occurs within the first four days of heparin administration and is the result of the direct aggregation effect of UFH on platelets. The platelet count is generally 100–150 × 10⁹/l. The patient is usually asymptomatic and thrombocytopenia resolves spontaneously in spite of continuation of heparin treatment. The severe heparin induced thrombocytopenia occurs five or more days after starting heparin treatment (or sooner with re-exposure to heparin). It is caused by heparin dependent IgG antibodies that activate platelets leading to arterial or venous thrombus formation. It differs from other types of drug induced thrombocytopenia as it gives rise to both arterial or venous thrombosis as well as haemorrhagic complications. The platelet count is below 100 × 10⁹/l or less than half of the pretreatment value. In established cases, heparin must be stopped, and danaparoid (a heparinoid said to be free of contaminating heparin) or recombinant hirudin (lepirudin) given for temporary anticoagulation. Administering oral anticoagulants in the acute phase of heparin induced thrombocytopenia may actually aggravate the thrombotic tendency, possibly by suppressing protein C synthesis. Adjunctive measures include manoeuvres to salvage ischaemic limbs (thrombectomy or thrombolysis), plasmapheresis, and antiplatelet drugs. Platelet transfusion may worsen the problem and should be avoided. The complications and morbidity related to the heparin induced thrombocytopenia can be prevented if thrombocytopenia is recognised and heparin stopped immediately. It is therefore essential to monitor
Like UFH, LMWH produces its major anticoagulant response of a given dose correlates with the presence of renal failure or extreme obesity. LMWH is progressively replacing standard UFH for treatment of venous thromboembolism. Because virtually all molecules of UFH have a molecular size distribution, the mean molecular weights, ratios of anti-fXa to anti-fIIa activity, and degree of binding to plasma proteins (table 2). Properties associated with one LMWH cannot be extrapolated to a different LMWH. For this reason, the findings of clinical trials apply only to the particular LMWH evaluated and should not be generalised to the LMWH at large.

Because of its relatively more pronounced anti-fXa effect, LMWH in the therapeutic doses cannot be monitored using the aPTT, which is determined by the antithrombin activity, and anti-fXa assay must be used. For treatment of active venous thromboembolism, the anti-fXa activity should be targeted to the range of 0.4–1.0 U/ml. The therapeutic index of LMWH (the potential for benefit versus the risk of bleeding) appears to be higher than that of standard UFH. The treatment is cost-effective (despite the higher costs of LMWH) and convenient since it allows early mobilisation and requires less nursing and laboratory supervision. LMWH interacts with platelets and platelet factor 4 less readily and the incidence of heparin induced thrombocytopenia is lower than with standard UFH. The incidence of osteopaenia during long term use also appears to be less than with UFH.

LMWH once or twice daily subcutaneously has been shown to be as effective and safe as standard full dose UFH in the treatment of proximal DVT and acute pulmonary embolism. Some unsolved issues remain to be addressed in specific trials before LMWHs can definitively replace UFH in the treatment of all forms of PE. The therapeutic role of LMWH in patients with massive pulmonary embolism who are haemodynamically unstable remains to be determined. Different preparations of LMWH vary with respect to their mean molecular weights, ratios of anti-fXa to anti-fIIa activity, and degree of binding to plasma proteins (table 2). Properties associated with one LMWH cannot be extrapolated to a different LMWH. For this reason, the findings of clinical trials apply only to the particular LMWH evaluated and should not be generalised to the LMWH at large.

Because of its relatively more pronounced anti-fXa effect, LMWH in the therapeutic doses cannot be monitored using the aPTT, which is determined by the antithrombin activity, and anti-fXa assay must be used. For treatment of active venous thromboembolism, the anti-fXa activity should be targeted to the range of 0.4–1.0 U/ml. The therapeutic index of LMWH (the potential for benefit versus the risk of bleeding) appears to be higher than that of standard UFH. The treatment is cost-effective (despite the higher costs of LMWH) and convenient since it allows early mobilisation and requires less nursing and laboratory supervision. LMWH interacts with platelets and platelet factor 4 less readily and the incidence of heparin induced thrombocytopenia is lower than with standard UFH. The incidence of osteopaenia during long term use also appears to be less than with UFH.

LMWH once or twice daily subcutaneously has been shown to be as effective and safe as standard full dose UFH in the treatment of proximal DVT and acute pulmonary embolism. Some unsolved issues remain to be addressed in specific trials before LMWHs can definitively replace UFH in the treatment of all forms of PE. The therapeutic role of LMWH in patients with massive pulmonary embolism who are haemodynamically unstable remains to be determined. Different preparations of LMWH vary with respect to their mean molecular weights, ratios of anti-fXa to anti-fIIa activity, and degree of binding to plasma proteins (table 2). Properties associated with one LMWH cannot be extrapolated to a different LMWH. For this reason, the findings of clinical trials apply only to the particular LMWH evaluated and should not be generalised to the LMWH at large.

Clinical evaluation of highly specific, ATIII independent thrombin inhibitors, such as hirudin or hirudin fragments, is just beginning. Hirudin is a progenitor of a family of peptides that directly inhibit thrombin independent of an interaction with ATIII. These peptides, particularly the low molecular weight analogues, more effectively inhibit fibrin deposition in the interstices of a thrombus than does the larger heparin-ATIII complex. They are therefore more effective than heparin in inactivating thrombin bound to fibrin which is a potent stimulus for thrombus growth. Their dose–response curve exhibits linearity over a range greater than that of UFH, and the aPTT test is well suited to monitor their anticoagulant effect. Recombinant hirudin (lepirudin) is available for treatment of heparin induced thrombocytopenia. The half life of lepirudin is relatively short (about 1.3 hours), which is helpful in patients who develop bleeding or who require surgery or invasive procedures. There is no known antidote.
**Thrombolytic treatment**

Thrombolytic treatment, by actively dissolving the clot, has several potential advantages over anticoagulation in the treatment of patients with pulmonary embolism. By relieving pulmonary artery obstruction, thrombolysis can quickly reduce the load on the right ventricle and reverse right heart failure; consequently, it has the potential to prevent death in the haemodynamically unstable patient who would otherwise not survive the many hours or days required for spontaneous fibrinolysis. Thrombolytic treatment is reserved mainly for patients in whom there is evidence of a severely compromised circulation—for example, hypotension, oliguria or severe hypoxaemia. In patients with pulmonary embolism who also have major proximal DVT, thrombolytic treatment reduces the late morbidity from the thrombosis that often can be considerable. A further potential but unproven advantage of thrombolytic treatment over heparin in such patients is that it may reduce the chance of recurrent embolism by dissolving thrombus before it embolises, and so may reduce the chances of chronic thromboembolic pulmonary hypertension developing at a later date. Although some authorities widen the indication of thrombolysis to patients with pulmonary embolism who have echocardiographic evidence of right ventricular dysfunction, additional information is needed to determine whether right ventricular dysfunction, by itself, is an indication for thrombolysis.

Thrombolytic agents dissolve thrombi by activating plasminogen to plasmin. Plasmin, when in proximity to a thrombus or a haemostatic plug, degrades fibrin to soluble peptides. Circulating plasmin also degrades soluble fibrinogen and, to some extent, factors II, V, and VIII. Moreover, raised concentrations of fibrin and fibrinogen degradation products contribute to the coagulopathy by both inhibiting the conversion of fibrinogen to fibrin and interfering with fibrin polymerisation.

The thrombolytic agents currently in use are streptokinase, urokinase, recombinant tissue plasminogen activator (rt-PA, alteplase), anisoylated plasminogen streptokinase activator complex (APSAC, anistreplase), and reteplase. Streptokinase is a purified bacterial protein; it binds to plasminogen non-covalently to form an activator complex, which converts other plasminogen molecules to plasm. Streptokinase is antigenic and cannot be readministered for at least six months, as circulating antibodies may both inactivate the drug and produce allergic reactions. Urokinase is isolated from human urine or cultured embryonic renal cells; unlike streptokinase, urokinase is not antigenic and produces a lytic state by directly converting plasminogen to plasmin. rt-PA is produced by recombinant DNA technology; like urokinase, it is non-antigenic and directly converts plasminogen to plasmin, but it is more fibrin specific (that is, it produces less systemic plasminogen activation) than either streptokinase or urokinase. Fibrin specificity is relative, however, and systemic fibrinogenolysis may occur after the administration of rt-PA. Other thrombolytic agents are either not approved or only seldom used for the treatment of pulmonary embolism in most countries. Some new agents (so called second generation thrombolytics), notably mutants of t-PA (tenecteplase, lanoteplase), staphylokinase, and saruplase (prourokinase) are in clinical testing.

With the exception of one small study that is difficult to interpret, none of the trials comparing thrombolytic agents with UFH in pulmonary embolism has been large enough to detect any significant difference in the most important end point—mortality. Consequently, the degree of angiographic or scintigraphic resolution and changes in haemodynamics were used as surrogate measures. Accelerated early resolution of pulmonary embolism as compared with UFH has been proven in all these agents. However, this benefit is short lived and there is no difference after several days. Definite evidence that thrombolytic treatment as opposed to heparin reduces mortality in pulmonary embolism is lacking and it is unlikely to be forthcoming because of the logistic problems involved in mounting such a study. The low mortality at three months (<10%) of patients treated with UFH and oral anticoagulants has

<table>
<thead>
<tr>
<th>LMWH</th>
<th>Brand name</th>
<th>Mean molecular weight (daltons)</th>
<th>Ratio of anti-Xa to anti-IIa</th>
<th>Dosage in prophylaxis of VTE (subcutaneously)</th>
<th>Dosage in treatment of VTE (subcutaneously)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ardeparin</td>
<td>Normiflo</td>
<td>6000</td>
<td>1.9</td>
<td>50 U/kg q12h</td>
<td>130 U/kg q12h</td>
</tr>
<tr>
<td>Certoparin</td>
<td>Mono-Embolex</td>
<td>5200</td>
<td></td>
<td>3000 U qd</td>
<td>8000 U q12h</td>
</tr>
<tr>
<td>Dalteparin</td>
<td>Fragmin</td>
<td>6000</td>
<td>2.7</td>
<td>2500–5000 U qd</td>
<td>120 U/kg q12h or 200 U/kg qd</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>Lovenox, Clexane</td>
<td>4200</td>
<td>3.8</td>
<td>2000–4000 U qd</td>
<td>100 U/kg q12h</td>
</tr>
<tr>
<td>Nadroparin</td>
<td>Fraxiparin</td>
<td>4500</td>
<td>3.6</td>
<td>3100 U qd or 40–60 U/kg qd</td>
<td>&lt; 55 kg: 4000 U q12h; 55–80 kg: 6000 U q12h; &gt; 80 kg: 8000 U q12h</td>
</tr>
<tr>
<td>Reviparin</td>
<td>Clivar</td>
<td>4000</td>
<td>3.5</td>
<td>1750 U qd</td>
<td>&lt; 60 kg: 4200 U q12h; &gt; 60 kg: 6300 U q12h</td>
</tr>
<tr>
<td>Tinzaparin</td>
<td>Innohep, Logiparin</td>
<td>6500</td>
<td>1.9</td>
<td>3500 U qd or 50 U/kg qd</td>
<td>175 U/kg qd</td>
</tr>
</tbody>
</table>

VTE, venous thromboembolism; U, international anti-Xa units; qd, every day; q12h, every 12 hours

Table 2: Low molecular weight heparins (LMWH)
always precluded the identification of a mortality effect of thrombolytic treatment when a relatively small number of patients were studied. A further factor contributing to the lack of significant reduction of mortality despite impressive early acceleration of thrombus resolution is that patients who survive long enough to be entered into a clinical trial probably make up a group with an improved prognosis, since the most severely affected patients will have died before receiving treatment. Therefore, the numbers of patients required to demonstrate a difference in mortality far exceeds the numbers treated in the centres.

There is only some indirect evidence of better prognosis with thrombolysis. The rate of treatment failure (that is, progression to a new form of treatment such as heparin to thrombolysis or thrombolysis to embolectomy) in patients with very severe pulmonary embolism is lower in those treated with thrombolysis than in those who receive UFH. Further indirect evidence comes from a non-randomised study (multicentre registry) of 719 patients without shock, in which 169 patients initially received thrombolitics and 550 were treated with heparin alone. In the group undergoing thrombolysis, mortality at 30 days was significantly lower (4.7% vs 11.1%) and recurrent pulmonary embolism significantly less frequent (7.7% vs 18.7%) than in the heparin treated group. Therefore, a more rapid resolution of pulmonary embolism seems desirable, because prolonged haemodynamic disturbance can only cause harm, and if further emboli develop their haemodynamic effect will be lessened if previous emboli have been partially removed.

Several trials compared different thrombolitics or different dosages of a given thrombolytic. No clear cut advantage of a given drug or a given dosage has been found. rt-PA produces a faster improvement at 2–4 hours than urokinase, but at 12–24 hours there is no significant difference. All thrombolitics appear to be equally effective and safe when equivalent doses are delivered. It probably matters little which agent is used; it is much more important to ensure that patients receive it quickly.

With experiments showing that rt-PA produces continuing thrombolysis after it is cleared from the circulation, and that thrombolysis is both increased and accelerated, and bleeding reduced when the drug is administered over a short period, interest was awakened in using very high doses over a short interval. The rationale supporting such treatment as opposed to prolonged infusion is that the initially high concentration of the drug overwhels plasminogen activator inhibitor-1 and renders negligible any attenuating effects of this inhibitor on the drug activity. The higher peak plasma concentration results in a higher concentration of the activator on the surface and inside the thrombi. Further, the bolus is cleared rapidly from the circulation, thus preventing large amounts of degradation products from the lysed emboli interacting with continuously infused plasminogen activator which converts circulating (rather than fibrin bound) plasminogen to plasmin, and in turn, induces the systemic lytic state. However, all studies to date failed to show any significant difference in the early resolution of pulmonary embolism or in bleeding complications. No trial has assessed use of a large bolus dose of streptokinase which, as in the treatment of myocardial infarction, would probably be just as effective and considerably cheaper.

Before initiation of thrombolytic treatment, prothrombin time, aPTT, fibrinogen, and platelets should be measured to make sure that there is no pre-existing coagulation disorder which would complicate thrombolysis. Contraindications include intracranial or intraspinal disease, active internal bleeding, recent major surgery or trauma (within 10 days), and uncontrolled severe hypertension. A blood sample should also be obtained for haemoglobin and for blood typing in case transfusion is required. When streptokinase or APSAC is used, 100 mg hydrocortisone reduces the incidence of side effects. Both agents are not recommended for repeated use or after a recent streptococcal infection.

In contrast to myocardial infarction, thrombolysis in acute massive pulmonary embolism appears effective for up to 10–14 days after the onset of symptoms. Thrombolytics are equally effective when given through a peripheral vein or via a catheter in the pulmonary artery. Generally accepted fixed dosage regimens are given in table 3. There is no need to obtain clotting tests during treatment as such tests are of no value in predicting complications or adjusting dosage. After the conclusion of the thrombolytic treatment, measurements of aPTT and fibrinogen are mandatory in order to determine when heparin (without a bolus) should be instituted. If the post-thrombolysis aPTT exceeds twice the upper limit of normal or the fibrinogen concentration is below 180, these tests should be repeated every four hours until they reach these concentrations, at which point heparin can be started (or resumed) safely. After the patient has been adequately heparinised, oral anticoagulation is initiated; even if the prothrombin time quickly reaches the target range, it should overlap with heparin for at least five days.

The main complication of thrombolytic treatment is bleeding. All thromboembolics are administered in regimens that are designed to activate fibrinolysis systematically throughout the body. None of these agents will distinguish a pathologic thrombus from a beneficial haemostatic plug. Although rt-PA and APSAC are somewhat more fibrin specific than streptokinase and urokinase, all agents have the

Table 3  Thrombolytic regimens for massive pulmonary embolism

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Streptokinase</td>
<td>250000 to 500000 U as a loading dose over 15 mins, followed by 100 000 U/h for 24 hours</td>
</tr>
<tr>
<td>Urokinase</td>
<td>4400 U/kg as a loading dose over 10 min., followed by 4400 U/kg/h for 12 hours</td>
</tr>
<tr>
<td>rt-PA</td>
<td>10 mg as a bolus, followed by 90 mg in a continuous infusion over 2 hours</td>
</tr>
<tr>
<td>APSAC</td>
<td>30 mg in 5 mins</td>
</tr>
<tr>
<td>Reteplace</td>
<td>Two bolus injections of 10 U, 30 mins apart</td>
</tr>
</tbody>
</table>

Before treatment, stop heparin.
potential to lyse a fresh platelet–fibrin plug anywhere and cause bleeding at this site. The two major factors which increase bleeding risk are prolonged administration of thrombolytics and the use of procedures which involve vessel puncture.

The reported incidence of haemorrhage has varied greatly. If major haemorrhage is arbitrarily defined as fatal bleeding, intracranial haemorrhage, or bleeding that requires either surgery or transfusion, the average overall incidence of major haemorrhage with pulmonary embolism thrombolysis is about 10%, and is similar among the thrombolytic agents used.

The incidence of cerebral bleeding is about 0.5–1.5% irrespective of the agent or ancillary treatment used. The elderly, patients with uncontrolled hypertension, and those with recent stroke or craniotomy appear to be at especially high risk for cerebral bleeding. Acute profuse gastrointestinal bleeding is usually the consequence of giving thrombolytics to a patient with unsuspected active peptic ulcer. Late bleeding (2–3 days) may be caused by stress ulceration, particularly in very ill patients; thrombolysis is probably irrelevant but subsequent anticoagulation makes things worse. More common than profuse gastrointestinal bleeding is “coffee ground” vomiting, which is often the result of a combination of thrombolysis and superficial gastric mucosal congestion and erosions, and tends to follow a benign clinical course. Iatrogenic bleeding ranges from trivial to life threatening. Rupture of the heart, liver or spleen during attempted resuscitation may lead to fatal bleeding. Arterial or venous puncture should be avoided if possible. Retropertioneal bleeding can occur during the femoral vein catheterisation for pulmonary angiography if an artery is inadvertently punctured above the inguinal ligament. Microscopic haematuria is common; microscopic haematuria is rare and may indicate an unsuspected urinary tract neoplasm.

Bleeding from vascular sites can usually be controlled with manual pressure or compression dressings. Management of severe bleeding from an inaccessible site dictates the reversal of thrombolysis. The basic principles are to stop the administration of the thrombolytic and any concomitant anticoagulation, to inhibit plasmin activity, and to replenish fibrinogen and coagulation factors. There is seldom time for elaborate laboratory tests but a prolonged cutaneous bleeding time is a useful bedside marker of continuing plasmin generation. Plasmin activity is inhibited with intravenous aprotinin, with or without additional tranexamic acid orally. Fibrinogen is replaced with fresh frozen plasma or fibrinogen concentrate, but since both of these contain plasminogen it is prudent to give a plasmin inhibitor first, or at least concurrently. Intracranial bleeding is an emergency, and a neurosurgical consultation must be obtained at the first sign of altered mental status or focal neurologic findings.

The second complication of thrombolytic treatment is an allergic reaction to either streptokinase or APSAC, which are bacterial proteins that regularly induce an antigenic response in man. Anaphylaxis is very rare (< 0.5%) but flushing, rashes, and fever are relatively common (5–7%). It is unclear whether these are true allergic reactions; they usually respond to hydrocortisone and an anti-histamine.

**Thrombolysis in pulmonary embolism**
- Thrombolysis is indicated in massive pulmonary embolism with right ventricular overload and hypotension
- Thrombolysis is effective up to 10 days after pulmonary embolism
- Laboratory monitoring and dosage adjustments during treatment are not necessary

**Pulmonary embolectomy**

Embolectomy continues to be undertaken in emergency situations when more conservative measures have failed. The only indication for embolectomy is to prevent death. Unfortunately, it is difficult to identify accurately those who will die without embolectomy. Certainly patients in extremis requiring prolonged resuscitation are indicated for embolectomy; there are only very few reports suggesting that such patients may survive with thrombolytic treatment. Patients who deteriorate haemodynamically after the start of thrombolytic treatment, and whose blood pressure remains below 90 mm Hg in spite of vasopressors, would also seem candidates for surgical intervention. Further, there are still patients in whom thrombolytic treatment is contraindicated or too slow in producing benefit. In all these patients, every attempt should be made to confirm the diagnosis of massive pulmonary embolism before surgery, even if it requires partial cardiopulmonary bypass while definitive diagnostic procedures are being performed. Mortality of patients referred for embolectomy with an incorrect diagnosis approaches 100%.

Statistics regarding mortality following embolectomy are difficult to compare. Data are largely derived from retrospective reviews of historical series, often predating the advent of thrombolysis. In some series, considerable numbers of patients have been operated on more than 24 hours after embolism, questioning the need for the procedure. The results depend greatly on the indications used and the haemodynamic impairment of the patients. Mortality will be high in those patients most in need of embolectomy, and low in patients who would survive without it. Until 1985, the overall mortality was 51% for those done without, and 40% for those done with cardiopulmonary bypass. These results have been improved in recent years, mainly due to routine administration of vasopressors before the induction of anaesthesia and to the use of partial (femorofemoral) bypass in moribund patients as a means of maintaining the circulation while the
patient and the equipment are prepared to get on to full bypass. There has been no randomised trial of embolectomy versus thrombolytic treatment and it is unlikely that one of value will ever be performed because of the relative scarcity of these patients.

The main predictor of operative death is cardiac arrest with the need for resuscitation before the operation. Provided the patients reach the operating room without requiring external cardiac massage the mortality is in the range of 0–33%, but it is between 43–84% in those resuscitated. Postoperative complications include acute respiratory distress syndrome (ARDS), mediastinitis, acute renal failure and, of particular concern, severe neurologic sequelae. Late morbidity of patients successfully operated upon is principally neurological in nature; late mortality is low.7

**Catheter transvenous embolectomy**

An alternative technique in patients with massive pulmonary embolism who still can sustain a blood pressure with vasopressor support is catheter embolectomy employing a large steerable catheter with a suction cup on its end, inserted via cutdown in the femoral or jugular vein. Syringe suction captures the embolus in the cup and holds it there while the catheter and the embolus are withdrawn. However, this procedure is rarely undertaken. The results of the only two studies published show that embolus extraction is achieved in about two thirds of the patients, and the mortality in these studies was about 30%.7

An alternative manoeuvre of attempting to fragment the embolus is certainly much easier. If angiography shows massive emboli in the main pulmonary arteries it may be possible to break these up, using a pigtail catheter and a guide wire or an angiographic basket. The rationale is that the cross sectional area of the pulmonary vascular bed increases progressively from proximal to distal. Thus the fragmented clot obstructs a smaller percentage of the whole cross sectional area of the pulmonary vascular bed when displaced distally. The pulmonary vascular resistance will thus decrease and the pulmonary blood flow increase. A further advantage of this mechanical disruption of emboli would be enhanced clot exposure to lytic treatment by creation of multiple channels within the emboli.

A number of rotational devices for percutaneous mechanical thrombolysis has been experimentally evaluated; they work by high speed clot fragmentation and aspiration. Embolectomy can also be accomplished with the use of a catheter that delivers high velocity jets of saline that draw the clot toward the catheter tip and subsequently pulverises it. None of these devices has been extensively used in patients to date.

**Oral anticoagulants**

Oral anticoagulants act in the liver by inhibiting the synthesis of four vitamin K dependent coagulant proteins (factors II, VII, IX, and X), and at least two vitamin K dependent anticoagulant factors, proteins C and S. They do not act immediately because time is required for coagulation factors already present in the plasma to be cleared. It is therefore essential to overlap oral anticoagulants with heparin for at least five days, even if the prothrombin time reaches the target range sooner (the level of protein C declines quickly after initiation of oral anticoagulants, creating a thrombogenic potential).

The prothrombin time, used to adjust the dose of oral anticoagulation, should be reported according to the INR, not the prothrombin time ratio or the prothrombin time expressed in seconds. The INR is essentially a “corrected” prothrombin time that adjusts for the many different assays used. Effective treatment of venous thromboembolism is reflected by an INR of 2.0–3.0. Every effort should be made to maintain the patient in this range. This is facilitated by always aiming for an INR level that is in the mid-level of the INR range (that is, 2.5). Patients with the antiphospholipid syndrome may require a higher INR (2.5–3.5). In some settings, home monitoring of INR is convenient and cost-effective, and may ultimately improve anticoagulation control.

The duration of oral anticoagulation must be tailored to the individual patient. One should balance the risk of bleeding against the risk of recurrence when treatment is discontinued. The later risk includes not only the likelihood of recurrence but also its potential clinical effect; patients with cardiopulmonary disease might tolerate recurrent pulmonary embolism poorly. For most patients, provided there is no persisting risk factor, six months’ treatment is indicated. In patients whose risk factors can be interrupted—for example, transient immobilisation or oestrogen use—treatment may be shorter, but additional clinical trials to test this are needed. Certain groups may require longer or indefinite treatment, including patients with active tumours, thrombophilic disorders, those with proven recurrence of venous thromboembolism, and patients who have chronic thromboembolic pulmonary hypertension. The single best predictor of an increased risk for venous thromboembolism is a prior episode. Patients who have had one episode are at high risk to have another, whether or not they have a defined thrombophilic state.7

The risk of haemorrhage is always present and with long term treatment the cumulative risk of serious bleeding is not inconsequential (6–22 per 1000 patient months). The major determinants of oral anticoagulant induced bleeding are the intensity of the anticoagulant effect, the length of treatment, the patient’s underlying clinical disorder (past gastrointestinal bleeding, hypertension, cerebrovascular disease, renal insufficiency), advanced
treatment, as well as an appointment for anticoagulant supervision.

**Venous interruption**

Venous interruption procedures are designed to prevent emboli from reaching the lungs. They have no effect on the thrombotic process and do not prevent DVT. In the past the main methods were ligation, plication or the application of clips to the outside of the inferior vena cava. These procedures carried an appreciable mortality and morbidity, of which lower limb swelling after ligation was the worst. Nowadays the method of choice is the percutaneous placement of a filter in the inferior vena cava under fluoroscopic guidance.

There is no evidence that the filters have any advantages over anticoagulation for prophylaxis following an acute pulmonary embolism because the incidence of recurrence with anticoagulation alone is so low. Their place is in the rare case in which intensive and prolonged anticoagulation alone fails or adequate anticoagulation cannot be achieved because of strong contraindications (for example, serious multiple injuries, or during and after surgery). Although caval filtration is probably effective in these indications, there is a remarkable lack of controlled studies to support the use of this procedure.10 11

Devices placed in the inferior vena cava may perforate the vessel wall or migrate within and outside the venous system. Thrombosis occurs frequently at the venous access site. Pulmonary emboli, either passing through or around the therapeutic obstruction or originating proximally, have been reported with all these measures. Other late sequelae include caval thrombosis, filter fractures, and leg oedema. Because of the lack of controlled data regarding eventual outcome and the true incidence of complications, if a permanent filter is used long term clinical follow up is appropriate.

**Treatment of pulmonary embolism in pregnancy**

The management of venous thromboembolism during pregnancy remains controversial because of the lack of prospective trials. Heparin does not cross the placenta, and therefore does not have the potential to cause fetal bleeding or teratogenicity, although bleeding at the uteroplacental junction is possible. Oral anticoagulants cross the placenta and may cause fetal developmental abnormalities, fetal bleeding, spontaneous abortions, and stillbirth. Therefore, oral anticoagulants must not be administered in the first trimester of pregnancy (and preferably throughout the entire pregnancy), and all women of childbearing potential taking oral anticoagulants must avoid becoming pregnant.

Pregnant women with pulmonary embolism are best treated initially with continuous intravenous UFH or weight adjusted dose of...
subcutaneous LMWH, and then taught to self-administer LMWH once daily for the remainder of pregnancy until the onset of labour and further on in the puerperium. If possible, measurement of anti-FXa concentrations approximately four hours after injection and adjustment to a concentration of approximately 0.5–1.2 U/ml should be performed. A high index of suspicion for the development of osteopenia and a two weekly assessment of the platelet count is important. Heparin should be discontinued 24 hours before elective induction of labour. If spontaneous labour occurs in women receiving adjusted dose heparin, careful monitoring of the aPTT is required and, if it is prolonged near delivery, protamine may be required to reduce the risk of bleeding.10 11

Another acceptable approach is to give oral anticoagulants between the 13th and 36th week of gestation, and switch to heparin during the last two weeks of pregnancy. If the mother is admitted in premature labour while still on oral anticoagulants she should be given fresh frozen plasma. Treatment with oral anticoagulants can be resumed immediately after delivery, and continued for at least six weeks postpartum. Their effect on the baby persists for 7–14 days after they are stopped and therefore the baby should be given vitamin K at the time of delivery. Breast feeding is not contraindicated.

Current evidence suggests that thrombolyis is appropriate treatment for massive pulmonary embolism during pregnancy, but not within six hours of delivery or in the early postpartum period because of the high risk of bleeding complications.

The future

A widespread use of LMWHs for the treatment of acute pulmonary embolism is certain. Cost savings should prove substantial and will be directly proportional to the number of hospital days avoided. It is likely that heparinoids and specific thrombin inhibitors will replace UFH or LMWH for some indications, provided that their costs are not prohibitive. Decreased bleeding and less thromboembolic recurrence may also result as we gain experience with these new agents. It is also possible that synthetic thrombin inhibitors will be developed for oral use; this would open up the possibility for long term use. Optimal duration of anticoagulant treatment in different subgroups of patients with venous thromboembolism have yet to be determined. The risk/benefit ratio of the treatment of small subsegmental pulmonary embolism without residual DVT in the absence of persisting risk factors should be tested. Inhalation of nitric oxide or prostacyclin might prove to be a useful adjunct in the treatment of acute massive pulmonary embolism.

Abbreviations

APSAC: anisoylated plasminogen streptokinase activator complex (anistreplase)
ATIII: antithrombin III
aPTT: activated partial thromboplastin time
DVT: deep venous thrombosis
FIIa: activated factor II (thrombin)
FXa: activated factor X
INR: international normalised ratio
LMWH: low molecular weight heparin
rt-PA: alteplase
UFH: unfractionated heparin

   • Recommendations of the ACCP consensus conference on antithrombotic treatment.
   • Further recommendations of the ACCP consensus conference on antithrombotic treatment.
   • The first study showing that LMWH (nadroparin) is as effective and safe as UFH in the treatment of submassive pulmonary embolism.
   • In this randomised trial on 1021 patients, fixed dose subcutaneous reviparin given twice daily was as effective and safe as dose adjusted intravenous UFH for the initial management of venous thromboembolism, regardless of whether the patient had pulmonary embolism or a history of venous thromboembolism.
   • In a randomised study involving 612 patients with acute pulmonary embolism, initial subcutaneous treatment with tinzaparin in a dose of 175 U/kg once daily was as effective and safe as dose adjusted intravenous UFH.
   • In this double blind randomized trial on 200 patients, tinzaparin given in a dose of 175 U/kg once daily subcutaneously was probably more effective than dose adjusted intravenous UFH for preventing recurrent venous thromboembolism in patients with pulmonary embolism associated with proximal DVT.
   • An analysis and review of all reports on pulmonary embolism and of all randomised trials of thrombolysis in pulmonary embolism.
   • This study demonstrates a survival advantage and reduced risk of recurrence with thrombolytic treatment in patients with pulmonary embolism but without shock. Because of its non-randomised design and selection bias, however, this study has several important limitations.
   • Recommendations of the ACCP consensus conference on antithrombotic treatment.
   • Comprehensive guidelines with practical algorithms on diagnosis and management.
   • A comprehensive and authoritative “consensus” review with extensive literature references.